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INTRODUCTION 
Currently, more than 70% of drugs in R&D show extremely 
low solubility in water, which ultimately compromise their 
bioavailability in the human body. To minimize this 
problem several techniques have been considered in the last 
years, namely the production of solvates, polymorphs or 
eutectic mixtures. Among these techniques, the production 
of amorphous materials has been established as one of the 
most promising approaches to enhance the solubility of 
such drugs. Despite the large increase in solubility 
presented by the material in the amorphous state, they are 
highly instable thus preventing or making their use 
problematic in the pharmaceutical industry due to short and 
unpredictable stability prior to conversion into a more 
stable state. Co-amorphous systems have been studied for 
the last 10 years as an alternative strategy to delay and 
prevent the recrystallization of the drug. Co-amorphous are 
mixtures of a drug molecule and a co-former which can be 
either a second drug or a low molecular weight excipient. 
The potential establishment of bonds between compounds 
(e.g. hydrogen bonds) is expected to promote the stability 
of the composite material. The choice between the 
formation of an amorphous or a co-amorphous system 
depends on the drug and its therapeutic use. 
The present work aimed at the development of a monitoring 
strategy to evaluate the recrystallization tendency of the co-
amorphous olanzapine (OLZ), a BCS class II drug, and 
saccharin (SAC).  
 
MATERIALS AND METHODS 
A mixture comprising olanzapine and saccharin in a 1:1 
molar ratio was dissolved in dichloromethane and then the 
co-amorphization was carried out by evaporation of the 
solvent. The product obtained was characterized by 
differential scanning calorimetry (DSC) and X-ray powder 
diffraction (XRPD) to verify the production of a 
coamorphous entity.  
 
Different amounts of the OLZ:SAC co-amorphous powder 
(0-15.8%) were blended with anhydrous dibasic calcium 
phosphate (46.3%), microcrystalline cellulose (33.7%) and 
povidone (4.2%) (Table 1). The fraction of OLZ:SAC in the 
formulation was kept constant by the addition of crystalline 
OLZ (0-10.0%) and SAC (0-5.8%). Additionally, different 
fractions of water were also added to the final mixtures 
immediately before the analysis of the wet masses. 
 
Exp. Amorphous OLZ (%, OLZ basis) 
H2O  
(%, dry basis) 
1 0.0 0.0 
2 0.0 20.0 
3 0.0 40.0 
9 25.0 0.0 
10 25.0 20.0 
11 25.0 40.0 
13 50.0 0.0 
14 50.0 20.0 
15 50.0 40.0 
16 62.5 0.0 
19 75.0 20.0 
26 100.0 20.0 
27 100.0 40.0 
Table 1. Part of the Design of Experiments (DoE) matrix 
considered for the development of the monitoring strategy. 
 
Near infrared spectroscopy (NIR) and Fourier transform 
infrared spectroscopy (FTIR) were considered to evaluate 
spectral differences between the various formulations 
containing different fractions of crystalline /amorphous 
OLZ. Correlations were obtained when Partial Least Square 
Regression (PLS-R) methodology was applied enabling the 
development of the model. 
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RESULTS AND DISCUSSION 
After processing all spectra with a second order derivative 
filter it was possible to obtain a correlation between the 
spectral regions 4700-4000 cm-1 and 6200-5600 cm-1 and 
the quantity of amorphous and crystalline olanzapine 
present in each sample (Figure 1).  
 
 
Figure 1. Part of the 2nd derivative spectra (4470-4420cm-1) for 
0% amorphous olanzapine (red), 25% amorphous olanzapine 
(green), 50% amorphous olanzapine (blue), 75% amorphous 
olanzapine (pink) and 100% amorphous olanzapine (yellow). 
 
 
Figure 2. Differences obtained between the expected and the 
predicted amorphous contents when the model was used. 
 
The high coefficient of correlation found for the model 
(R2=0,998) and the low error of validation for the predicted 
samples, i.e., samples which were not used for the 
calibration of the model (<5%, Figure 2) proved the 
sensitivity of the method to evaluate the fraction of 
crystalline OLZ, predicting both the amorphous and the 
crystalline fractions of olanzapine in the different mixtures. 
CONCLUSION 
The work has provided a model to allow a quick, non-
destructive and effective method to monitor the 
recrystallization of amorphous OLZ present in formulations 
as co-amorphous entities. 
The application of spectroscopic analysis (NIR and FTIR) 
enabled the quantification of crystalline /amorphous OLZ in 
dry and wet mixtures. 
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